© Copyright 2025 American Medical Association. All rights reserved.
| Short Descr | NFCT DS DNA&RNA 21 SARSCOV2 | Medium Descr | NFCT DS DNA&RNA 21 TARGETS SARS-COV-2 AMP PROBE | Long Descr | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GZ | Item or service expected to be denied as not reasonable and necessary | GA | Waiver of liability statement issued as required by payer policy, individual case |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Added | First appearance in code book. |
| 2022-01-01 | Note | Grammar correction |
| 2021-01-01 | Added | First appearance of code in CPT® Code Set. |
| 2020-08-10 | Added | Code added. |
Get instant expert-level medical coding assistance.